Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3
- PMID: 18691577
- DOI: 10.1016/j.febslet.2008.07.051
Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3
Abstract
This study describes a strategy to develop LNA-modified small interfering RNA (siRNAs) against the highly structured 5' UTR of coxsackievirus B3 (CVB-3), which is an attractive target site due to its high degree of conservation. Accessible sites were identified based on structural models and RNase H assays with DNA oligonucleotides. Subsequently, LNA gapmers, siRNAs, siLNAs and small internally segmented interfering RNA (sisiLNAs) were designed against sites, which were found to be accessible in the in vitro assays, and tested in reporter assays and experiments with the infectious virus. The best siLNA improved viability of infected cells by 92% and exerted good antiviral activity in plaque reduction assays.
Similar articles
-
Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.PLoS One. 2015 Aug 26;10(8):e0136395. doi: 10.1371/journal.pone.0136395. eCollection 2015. PLoS One. 2015. PMID: 26308932 Free PMC article.
-
Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3.FEBS Lett. 2010 Feb 5;584(3):591-8. doi: 10.1016/j.febslet.2009.12.007. Epub 2010 Jan 13. FEBS Lett. 2010. PMID: 20005874
-
Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor.Biol Chem. 2005 Sep;386(9):857-63. doi: 10.1515/BC.2005.100. Biol Chem. 2005. PMID: 16164410
-
Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses.Curr Opin Mol Ther. 2006 Apr;8(2):104-7. Curr Opin Mol Ther. 2006. PMID: 16610761 Review.
-
siRNAs: a new wave of RNA-based therapeutics.J Antimicrob Chemother. 2003 Apr;51(4):753-6. doi: 10.1093/jac/dkg166. Epub 2003 Mar 13. J Antimicrob Chemother. 2003. PMID: 12654731 Review. No abstract available.
Cited by
-
Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Front Microbiol. 2022 Oct 26;13:915202. doi: 10.3389/fmicb.2022.915202. eCollection 2022. Front Microbiol. 2022. PMID: 36386681 Free PMC article.
-
Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2.Epigenomics. 2020 Aug;12(15):1349-1361. doi: 10.2217/epi-2020-0162. Epub 2020 Sep 2. Epigenomics. 2020. PMID: 32875809 Free PMC article. Review.
-
Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.PLoS One. 2015 Aug 26;10(8):e0136395. doi: 10.1371/journal.pone.0136395. eCollection 2015. PLoS One. 2015. PMID: 26308932 Free PMC article.
-
The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs.J Biomed Sci. 2012 Aug 13;19(1):73. doi: 10.1186/1423-0127-19-73. J Biomed Sci. 2012. PMID: 22889374 Free PMC article.
-
Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.Molecules. 2011 Oct 11;16(10):8475-503. doi: 10.3390/molecules16108475. Molecules. 2011. PMID: 21989310 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
